Vitamin D may slow progression of low-grade prostate tumors
the ONA take:
Vitamin D supplements may slow or even reverse the progression of low-grade prostate cancer without the use of radiation or surgery, new research presented at the 249th National Meeting & Exposition of the American Chemical Society (ACS) in Denver, Colorado has shown.
For the randomized, controlled clinical trial, researchers assigned 37 men with low-grade prostate cancer undergoing elective prostatectomies to receive either 4,000U of vitamin D daily or placebo during the 60-day waiting period prior to surgery. The patients' prostate glands were then removed and examined.
Results showed that men who received vitamin D showed improvements in their prostate tumors while those in the placebo group experienced no changes or their tumors got worse.
The findings suggest that vitamin D supplementation, well below pharmacological levels, may improve less aggressive prostate cancer by decreasing inflammation. It is not clear yet whether vitamin D prevents or treats prostate cancer, but it can prevent lower-grade tumors from becoming aggressive.
Vitamin D supplements may slow or even reverse the progression of low-grade prostate cancer without the use of radiation or surgery.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|